Healthcare
US clearance for Belfast technology that helps detect heart rhythm disorders
Belfast-based PulseAI secured FDA clearance for software that helps clinicians interpret wearable-device ECG data for heart-rhythm assessment.
PulseAI, a Belfast medical-technology company founded in 2020 by Ulster University alumnus Alan Kennedy, received US Food and Drug Administration clearance for its AI-powered software. The technology helps doctors interpret ECG readings generated by smartwatches and other wearable devices. FDA clearance allows the software to be sold in US markets. The application addresses a growing stream of cardiac data produced outside traditional clinical settings. By helping clinicians make sense of wearable ECG information, the system could support the assessment of heart-rhythm disorders. The development matters because consumer wearables are generating increasingly large volumes of physiological measurements, creating a need for software that can translate those readings into clinically useful information. The source identifies the regulatory milestone but does not provide diagnostic-performance figures, deployment numbers or details of the specific FDA classification.
Original source: The Irish News